Kairos Pharma, Ltd. ( KAPA ) stock is trading higher on Tuesday, with a strong session volume of 221 million compared to the average volume of 874.3K as per data from Benzinga Pro.

The company on Tuesday released safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first 10 enrolled patients.

Thus far, no dose-limiting toxicities or unexpected adverse events have been reported.

In addition, the treatment-related side effects were manageable with standard supportive care. Notably, no Grade 3 or 4 toxicities were observed.

The randomized Phase 2 trial aims to enroll 100 patients.

The study is designed to evaluate the safety, tolerability and early signs of efficacy of ENV-105, a CD105 antagonist, in men whose disease has progressed following standard hormone-based therapies.

Interim efficacy data from the trial are expected to be reported in September 2025.

Kairos Pharma ( KAPA ) plans to engage with regulatory agencies to discuss the design of a potential pivotal Phase 3 study, based on emerging data.

How To Buy KAPA Stock

By now, you're likely curious about how to participate in the market for Kairos Pharma ( KAPA ) — be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Kairos Pharma ( KAPA ), which is trading at $1.12 at time of writing the article, $100 would buy you 89.29 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading; either way, it allows you to profit from the share price decline.

KAPA Price Action: Kairos stock is up 57.64% at $1.08 at publication on Tuesday.

Read Next:

How Chewy’s Smart Moves Could Capture Over $1 Billion In Revenue